

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Kalyesubula, Robert; Hau, Jeffrey; Asiki, Gershim; Ssebunya, Billy; Kusemererwa, Sylvia; Seeley, Janet; Smeeth, Liam; Tomlinson, Laurie; Newton, Robert; (2019) Impaired renal function in a rural Ugandan population cohort. Wellcome Open Research, 3. p. 149. DOI: <https://doi.org/10.12688/wellcomeopenres.14863.2>

Downloaded from: <http://researchonline.lshtm.ac.uk/4652552/>

DOI: <https://doi.org/10.12688/wellcomeopenres.14863.2>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).






Available under license: <http://creativecommons.org/licenses/by/2.5/>

<https://researchonline.lshtm.ac.uk>



## RESEARCH ARTICLE

# REVISSED Impaired renal function in a rural Ugandan population cohort [version 2; referees: 1 approved, 1 approved with reservations]

Robert Kalyesubula<sup>1-3</sup>, Jeffrey P. Hau<sup>1</sup>, Gershim Asiki <sup>1,4</sup>, Billy Ssebunya<sup>1</sup>, Sylvia Kusemererwa <sup>1</sup>, Janet Seeley <sup>5</sup>, Liam Smeeth <sup>3</sup>, Laurie Tomlinson <sup>3</sup>, Robert Newton<sup>1,6</sup>

<sup>1</sup>MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda

<sup>2</sup>Department of Physiology, Makerere University College of Health Sciences, Kampala, Uganda

<sup>3</sup>Non-Communicable Disease Epidemiology, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK

<sup>4</sup>African Population and Health Research Center, Nairobi, Kenya

<sup>5</sup>Global Health and Development Department, London School of Hygiene and Tropical Medicine, London, UK

<sup>6</sup>University of York, York, UK

**v2** First published: 19 Nov 2018, 3:149 (<https://doi.org/10.12688/wellcomeopenres.14863.1>)

Latest published: 03 Jan 2019, 3:149 (<https://doi.org/10.12688/wellcomeopenres.14863.2>)

## Abstract





**Background:** Kidney disease is an important cause of morbidity and mortality globally. However, there are limited data on the prevalence of impaired kidney function in sub-Saharan Africa. We aimed to determine the prevalence of reduced kidney function and associated factors in a rural Ugandan population.

**Methods:** We undertook a study of a representative sample of the General Population Cohort in South-western Uganda. We systematically collected data on cardiovascular disease risk factors, anthropometric measurements and blood tests including haemoglobin, HIV, HbA1c and serum creatinine. The estimated glomerular filtration rate (eGFR) was calculated using the CKD-Epi formula, without the race component of the equation.

**Results:** A total of 5,979/6,397 (93.5%) participants had valid creatinine results. The mean age was 39 years (Range: 16-103 years) and 3,627 (60.7%) were female. HIV prevalence was 9.7% and about 40% of the population were pre-hypertensive or hypertensive. The mean serum creatinine level was 0.75 mg/dl (95% CI 0.74–0.75), and the average eGFR was 109.3 ml/min/1.73 m<sup>2</sup> (95% CI 108.8–109.9). The overall prevalence of eGFR <60 ml/min/1.73 m<sup>2</sup> was 1.64% (98/5,979) (95% CI 1.34–1.99). Additionally, 4,792 (80.2%) were classified as normal eGFR (≥90 ml/min/1.73 m<sup>2</sup>), 1,089 (18.2%) as low eGFR (60–89 ml/min/1.73 m<sup>2</sup>), 91 (1.52%) as moderately reduced eGFR (30–59 ml/min/1.73 m<sup>2</sup>), 4 (0.07%) as severely reduced eGFR (15–29 ml/min/1.73 m<sup>2</sup>), and 3 (0.05%) classified as having kidney failure (eGFR <15 ml/min/1.73 m<sup>2</sup>). When age-standardised to the WHO Standard Population the prevalence of eGFR <60 ml/min/1.73 m<sup>2</sup> was 1.79%. Age above 35 years and the presence of hypertension (OR 2.86, 95% CI 1.15-7.08) and anaemia (OR 2.14, 95% CI

## Open Peer Review

Referee Status:  

	Invited Referees	
	1	2
<b>version 2</b> published 03 Jan 2019	 report	 report
<b>version 1</b> published 19 Nov 2018	 report	 report

- 1 **John Feehally**, University of Leicester, UK
- 2 **Kajiru G Kilonzo**, Kilimanjaro Christian Medical Center, Tanzania

## Discuss this article

Comments (0)

1.12-4.09) were associated with eGFR<60 ml/min/1.73 m<sup>2</sup>.

**Conclusion:** In a systematic survey of people in rural Uganda, we found a substantial proportion had eGFR<60 ml/min/1.73 m<sup>2</sup>, and this was strongly associated with high blood pressure and anaemia.

### Keywords

Kidney disease, population cohort, epidemiology, prevalence

**Corresponding author:** Robert Kalyesubula ([rkalyesubula@gmail.com](mailto:rkalyesubula@gmail.com))

**Author roles:** **Kalyesubula R:** Conceptualization, Formal Analysis, Investigation, Methodology, Project Administration, Writing – Original Draft Preparation, Writing – Review & Editing; **Hau JP:** Formal Analysis, Writing – Original Draft Preparation, Writing – Review & Editing; **Asiki G:** Data Curation, Investigation, Methodology, Project Administration; **Ssebunya B:** Investigation, Project Administration, Writing – Original Draft Preparation; **Kusemererwa S:** Investigation, Methodology, Project Administration, Writing – Review & Editing; **Seeley J:** Conceptualization, Investigation, Project Administration, Supervision, Writing – Review & Editing; **Smeeth L:** Methodology, Supervision, Writing – Review & Editing; **Tomlinson L:** Investigation, Methodology, Project Administration, Supervision, Writing – Review & Editing; **Newton R:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** RK is funded by a grant from GlaxoSmithKline Africa Non-Communicable Disease Open Lab (Project Number: 8111) as part of a broader multicenter collaborative study between South Africa, Uganda, Malawi and the London School of Hygiene and Tropical Medicine which is collectively identified as the African Research in Kidney Disease (ARK) Network. LAT is funded by a Wellcome Trust intermediate clinical fellowship (101143/Z/13/Z).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2019 Kalyesubula R *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Kalyesubula R, Hau JP, Asiki G *et al.* **Impaired renal function in a rural Ugandan population cohort [version 2; referees: 1 approved, 1 approved with reservations]** Wellcome Open Research 2019, 3:149 (<https://doi.org/10.12688/wellcomeopenres.14863.2>)

**First published:** 19 Nov 2018, 3:149 (<https://doi.org/10.12688/wellcomeopenres.14863.1>)

**REVISED Amendments from Version 1**

We have responded to reviewer comments by making clear that we have measured the prevalence of impaired renal function, defined by one measure of eGFR, as opposed to chronic kidney disease which requires two measures more than 3 months apart. We have also discussed in more depth the need for better studies to determine the prevalence of renal disease across sub-Saharan Africa. We have also made minor corrections to the paper and supplementary tables.

**See referee reports**

## Introduction

Chronic kidney disease (CKD) is an under-recognized non-communicable disease, associated with a high morbidity and mortality. It is estimated that one in ten people are living with kidney disease worldwide and the prevalence may be higher in low-income countries such as Uganda<sup>1,2</sup>. However, as shown in a recent systematic review the quality of data is often poor, frequently using convenience samples in high-risk populations<sup>3</sup>. Furthermore, only 2% of the studies included in this review used the CKD-EPI formula for calculation of estimated glomerular filtration rate (eGFR) which, based on limited data, has been found to be the best estimate of population CKD prevalence<sup>3,4</sup>. Community-based studies of the prevalence of impaired renal function have shown marked variation in results. Among people living with HIV/AIDS, estimates range from 0.7% in Rakai, Central Uganda, 14.4% in Gulu, Northern Uganda, 26.5% in Zambia to 41.3% in Tanzania<sup>5–8</sup>. Among HIV-negative populations, estimates range from 2.5% in Wakiso, Central Uganda to 26.5% in Tanzania<sup>8,9</sup>. Hospital-based studies from a National Referral Hospital in Uganda show that most patients with kidney disease are young and have advanced disease by the time of presentation<sup>10</sup>. Thus, in sub-Saharan Africa estimates of kidney disease prevalence vary widely depending on the methods used to determine renal function and the population studied, in particular the age distribution<sup>8,11–19</sup>.

Globally, among the known key risk factors for CKD are diabetes mellitus, hypertension and infections such as HIV. Hypertension and HIV are important problems in Uganda with hypertension prevalence estimated to be 26.4%<sup>20</sup> and rising among those with HIV-infection<sup>21</sup>. However, the prevalence of diabetes mellitus is low compared to high-income countries at 2%<sup>22</sup>. Moreover, some studies have also highlighted differences in the prevalence of impaired renal function between urban and rural areas in Africa. A study from Cameroon found the overall prevalence of CKD to be 13.2%: 14.1% and 10.9% among rural and urban dwellers, respectively<sup>23</sup>. Late diagnosis, along with limited health care leading to poor control of hypertension and diabetes may be possible drivers of a higher prevalence in rural populations.

Therefore, we aimed to determine the prevalence and associations of impaired renal function among a representative sample of a rural area of Uganda, within an existing population cohort using high quality sampling methods.

## Methods

### Study design and setting

The General Population Cohort (GPC) was established in 1989, by the United Kingdom Medical Research Council and the Uganda Virus Research Institute, in Kalungu District, South-western Uganda<sup>24</sup>. The cohort was initially established to examine prevalence, incidence, risk factors and trends of infection with HIV in a rural African population. More recently, research activity has broadened to include the epidemiology and genetics of other communicable and of non-communicable diseases, including cancer, cardiovascular disease and diabetes<sup>24,25</sup>. In brief, the GPC is a community-based open cohort study of residents of 25 neighbouring villages within one-half of a sub-county, lying about 40 km from Lake Victoria. The population is scattered across the countryside in villages defined by administrative boundaries, with a few concentrated in small trading centres. The population under survey includes approximately 22,000 people, less than half of whom are more than 13 years of age. The cohort is dynamic with new births, deaths and migration reported at each round of follow-up. Data are collected through an annual census, an annual questionnaire and serological survey from 1989–2011 and a biennial questionnaire and serological survey thereafter. Details of sexual behaviour, medical, sociodemographic and geographic factors are recorded. Blood specimens are obtained at each biennial survey. Serum is tested for HIV-1 and the remainder is stored at -80°C. Since 1989, the seroprevalence of HIV has remained relatively stable in this population, with about 8% of participants infected; in recent years, prevalence has risen slightly, with the roll out of antiretroviral therapy and consequent improvements in survival.

Variables used for analysis were extracted from two separate survey rounds of the GPC (2011–2012 and 2014–2015), and participants' information gathered from questionnaire and laboratory data of the survey rounds were linked by unique identifiers. For adults (18+ years for males and 16+ years for females), variables used to develop a socioeconomic score (SES), smoking status, alcohol consumption, fruit and vegetable intake and results of Hepatitis B and C tests were derived from the 2011–2012 survey round. Variables associated with participant's eGFR, age, maximum education level, current marital status, history of stroke, body mass index (BMI) and HIV status were based on the 2014–2015 survey round.

### Data collection

Data collected from the GPC questionnaire regarding sexual behaviour and lifestyle factors were self-reported ([Supplementary File 1](#)). Anthropometric measurements and blood tests were performed by trained interviewers/nurses using calibrated instruments and following standard operating procedures. We adapted the World Health Organization (WHO) STEP-wise approach to surveillance questionnaire to obtain socio-demographic characteristics, lifestyle (diet, tobacco, and alcohol consumption), medical history and biophysical measurements. Blood pressure was measured using a digital sphygmomanometer (Omron M4-1). The participant had to be in a sitting position and the mean of the second and third readings taken at 5-minute

intervals was used for analysis. Body weight was measured using the Seca 761 mechanical scales and body height was measured using a stadiometer to the nearest 1 kg and 0.1 cm, respectively. Both scales were calibrated according to manufacturer guidelines weekly.

### Laboratory tests

Blood tests for haemoglobin, HIV screening, HbA1c, hepatitis B and C viruses, as well as the creatinine level were performed. Venous blood was tested for haemoglobin level using CT -5 Coulter Ac.T 5diff AL (Autoloader) [Beckman Coulter, North America]. HIV testing was performed using an approved national algorithm<sup>26</sup>. Hepatitis B surface antigen, Hepatitis C antibody and creatinine level were tested using a Cobas e 601 Auto Analyzer (Roche Diagnostics, North America). Creatinine was measured using the enzymatic method traceable to an isotope dilution mass spectrometry method<sup>27</sup>. The MRC/UVRI Entebbe laboratories currently have laboratory accreditation through ISO 15189 of the Kenya Accreditation Service, and are enrolled in external quality control programs for South Africa, America, Australia and the United Kingdom.

### Definitions and classification

Each participant's SES was derived from conducting principal component analysis (PCA) using variables relating to household infrastructure and property ownership. Urbanicity score used in this study was derived from a previous study using information from the Round 22 survey<sup>28</sup>. BMI was classified according to WHO categories (weight/height<sup>2</sup>: kg/m<sup>2</sup>): underweight (<18.5 kg/m<sup>2</sup>), normal weight (18.5–24.9 kg/m<sup>2</sup>), overweight (25.0–29.9 kg/m<sup>2</sup>) and obese (>30.0 kg/m<sup>2</sup>). Blood pressure (BP) classification was derived from the National Institute of Health guidelines: Pre-Hypertension was defined as having a systolic BP greater than 120mmHg but less than 140 mmHg, and a diastolic BP greater than 80 mmHg but less than 90 mmHg. Hypertension was defined as having a diastolic BP greater than or equal to 90 mmHg, systolic BP greater than or equal to 140 mmHg or being on treatment for high BP. Anaemia was defined as having haemoglobin levels less than 130 g/l in men, 120 g/l in non-pregnant women, and 110 g/l in pregnant women. Diabetes mellitus was diagnosed by either having HbA1c >6.5%, through self-reported measures of being previously diagnosed with diabetes, or by current treatment for diabetes.

### Classification of renal function

The estimated glomerular filtration rate (eGFR) was calculated using the CKD-Epi formula, without use of the coefficient for African Americans<sup>29</sup>. Impaired renal function was divided into five categories analogous to CKD stages, based on the National Kidney Foundation guidelines (without including proteinuria) as: normal eGFR ( $\geq 90$  ml/min/1.73 m<sup>2</sup>); low eGFR (60–89 ml/min/1.73 m<sup>2</sup>); moderately reduced eGFR (30–59 ml/min/1.73 m<sup>2</sup>); severely reduced eGFR (15–29 ml/min/1.73 m<sup>2</sup>); and kidney failure (eGFR <15 ml/min/1.73 m<sup>2</sup>)<sup>30</sup>.

### Statistical analysis

Baseline characteristics were tabulated stratified by sex. The prevalence of impaired renal function was also age standardised using the WHO world population as the reference.

We used logistic regression to estimate odd ratios (OR), along with its 95% confidence intervals (95% CIs), to identify potential factors independently associated with CKD. A forward step-wise approach was used in developing our multivariable model adjusting for age, sex, and all independent predictors of CKD.

We also conducted a secondary analysis to compare participants with eGFR <60 ml/min/1.73 m<sup>2</sup> to those with normal renal function excluding individuals in the low eGFR category. The population attributable fraction (PAF) of impaired renal function was estimated for hypertension, and anaemia using the adjusted odds ratios from the final multivariable model.

All statistical analyses were performed using STATA 13 SE (Stata Corp, Texas, USA).

### Ethical considerations

All study participants gave written informed consent to participate in the study. The study was approved by Uganda Virus Research Institute Research and Ethics Committee (UVRI-REC) and the Uganda National Council for Science and Technology (UNCST).

## Results

### Baseline characteristics of study participants

A total of 6,397 individuals participated in the Round 24 GPC survey in 2014–2015 and 5,979 (93.5%) individuals had valid creatinine test results. The average age of study participants was 39 years (range: 16 years to 103 years), consisting of 3,626 (60.7%) females. The majority of patients had primary-level education (60.4%). HIV prevalence was 9.7% (males: 8.4%, females: 10.5%) within this study population, and about 40% of the population was classified as pre-hypertensive. The mean serum creatinine level of the study population was 66.3 mmol/l (95% CI 65.4–66.3), and using the CKD-EPI equation, the average eGFR was 109.3 ml/min/1.73 m<sup>2</sup> (95% CI 108.8–109.9) (Table 1).

### Prevalence of impaired renal function

The overall prevalence of eGFR <60 ml/min per 1.73 m<sup>2</sup> was 1.6% (95% CI 1.34–1.99). Of the respondents, 4,792 (80.2%) were classified as normal, 1,089 (18.2%) as low eGFR, 91 (1.5%) as moderately reduced eGFR, 4 (0.1%) as severely reduced eGFR, and 3 (0.1%) classified as having kidney failure (Figure 1, Table 2). The prevalence of impaired renal function among those over the age of 16, age-standardised to the WHO population, was 1.8%.

### Factors associated with eGFR <60 ml/min per 1.73 m<sup>2</sup>

Age and sex adjusted associations with the presence of eGFR <60 ml/min per 1.73 m<sup>2</sup> are shown in Supplementary Table 1. In multivariable analysis, older age, hypertension (OR 2.86; 95% CI 1.15–7.08) and anaemia (OR 2.14 ; 95% CI 1.12–4.09) were independently associated with eGFR <60 ml/min per 1.73 m<sup>2</sup> (Table 3).

Age and sex adjusted associations of variables with the presence of eGFR of <90 mls/min/1.73m<sup>2</sup> are shown in Supplementary Table 2. In multivariable analysis, female sex (OR 1.56, 95% CI 1.27–1.93); older age, higher urbanicity score, being overweight

**Table 1.** Characteristics of participants with creatinine results from Survey round 24 among a general population cohort in rural Uganda (N=5,979).


Variable	Male, n (%)	Female, n (%)	Total, n (%)
<b>Age Group</b>			
<35	1,033 (43.90)	1,703 (46.97)	2,736 (45.77)
35–44	460 (19.55)	721 (19.88)	1,181 (19.74)
45–54	378 (16.02)	507 (13.98)	884 (14.79)
55–64	244 (10.37)	336 (9.27)	580 (9.70)
65–74	138 (5.86)	231 (6.37)	369 (6.17)
75+	101 (4.29)	128 (3.53)	229 (3.83)
<b>Max Education</b>			
None	137 (5.82)	394 (10.87)	531 (8.88)
Primary	1,488 (63.24)	2,122 (58.52)	3,610 (60.38)
Secondary	570 (24.21)	946 (26.09)	1,516 (25.35)
Higher Level	158 (6.71)	164 (4.52)	322 (5.38)
<b>Currently Married**</b>			
No	357 (20.62)	1,075 (36.68)	1,432 (30.72)
Yes	1,373 (79.36)	1,856 (63.32)	3,229 (69.28)
<b>Urbanicity*1</b>			
Quartile 1	513 (28.71)	756 (26.31)	1,259 (27.24)
Quartile 2	468 (26.19)	733 (25.86)	1,201 (25.98)
Quartile 3	436 (24.40)	697 (24.59)	1,133 (24.51)
Quartile 4	370 (20.71)	659 (23.25)	1,029 (22.26)
<b>SES*2</b>			
Lower	565 (35.76)	819 (32.79)	1,384 (33.94)
Middle	521 (33.04)	833 (33.35)	1,354 (33.23)
Upper	493 (31.20)	846 (33.87)	1,339 (32.83)
<b>BMI*3**</b>			
Normal weight	1,786 (76.47)	2,290 (65.84)	4,076 (70.11)
Underweight	407 (17.42)	302 (8.68)	709 (12.19)
Overweight	122 (5.22)	648 (18.63)	770 (13.24)
Obese	21 (0.90)	238 (6.84)	259 (4.45)
<b>Blood Pressure*4</b>			
Normal	668 (40.44)	1,235 (48.82)	1,903 (45.51)
Pre-Hypertension	719 (43.52)	944 (37.28)	1,663 (39.75)
Hypertension	265 (16.04)	352 (13.90)	617 (14.75)

Variable	Male, n (%)	Female, n (%)	Total, n (%)
<b>HIV Status**</b>			
Negative	2,150 (91.57)	3,242 (89.51)	5,392 (90.32)
Positive	198 (8.43)	380 (10.49)	578 (9.68)
<b>Hepatitis B*</b>			
Negative	1,588 (96.48)	2,479 (98.10)	4,067 (97.46)
Positive	58 (3.52)	48 (1.90)	106 (2.54)
<b>Hepatitis C*</b>			
Negative	1,582 (96.17)	2,439 (96.52)	4,021 (96.38)
Positive	63 (3.83)	88 (3.48)	151 (3.62)
<b>Anaemia*5</b>			
Negative	1,078 (86.87)	1,583 (83.40)	2,661 (84.77)
Positive	163 (13.13)	315 (16.60)	478 (15.23)
<b>Diabetes*6</b>			
No	1,603 (97.74)	2,467 (97.94)	4,070 (97.53)
Yes	37 (2.26)	52 (2.06)	89 (2.14)
<b>Current smoking status*</b>			
Not current smoker	1,301 (78.80)	2,478 (97.87)	3,779 (90.34)
Non-daily smoker	83 (5.03)	17 (0.67)	100 (2.39)
Daily smoker	267 (16.17)	37 (1.46)	304 (7.27)
<b>Alcohol consumption*</b>			
Never drinkers	831 (54.64)	1,589 (69.27)	2,420 (63.43)
No alcohol in past 30 days	90 (5.92)	250 (10.90)	340 (8.91)
Alcohol in past 30 days	600 (39.45)	455 (19.83)	1,055 (27.65)

\*Variables from a previous round (R22) of the GPC where total number of participants may vary: Urbanicity (n=4,622), SES (n=4,077), Blood Pressure (BP) (n=4,184), Hepatitis B (n=4,173), Hepatitis C (n=4,172), smoking status (n=4,183), alcohol consumption in the last 30 days (n=3,815), and anaemia (n=3,139). <sup>1</sup>Urbanicity score derived from Riha *et al.* (2014).

<sup>2</sup>Socio-economic Score (SES) derived from conducting Principle Component Analysis (PCA) on a statistical software using variables relating to household infrastructure and property ownership <sup>3</sup>Body Mass Index (BMI) Classification according to WHO (weight/height<sup>2</sup>: kg/m<sup>2</sup>): Underweight (<18.5 kg/m<sup>2</sup>), Normal weight (18.5–24.99 kg/m<sup>2</sup>), Overweight (25.0–29.99 kg/m<sup>2</sup>), Obese (>30.0 kg/m<sup>2</sup>). <sup>4</sup>BP classification derived from the National Institute of Health guidelines: Pre-Hypertension was defined as having a systolic BP >120 mmHg but <140 mmHg, and a diastolic BP >80 mmHg but <90 mmHg. Hypertension was defined as having a systolic BP ≥90 mmHg, diastolic BP ≥140 mmHg. <sup>5</sup>Anaemia was defined as having haemoglobin levels less than 130 g/L in men, 120 g/L in non-pregnant women, and 110 g/L in pregnant women. Only 2,064 individuals had anaemia results from the R24 of the GPC <sup>6</sup>Diabetes was defined as having HbA1C >6.5%, or being previously diagnosed with diabetes, or are currently on treatment for diabetes.

\*\*Variables in R24 with missing individuals: Currently Married (n=4,661), BMI (n=5,814), HIV (n=5,970)



**Figure 1.** Prevalence of estimated glomerular filtration rate <60 ml/min/1.73 m<sup>2</sup> by age group among a rural Ugandan cohort.

**Table 2.** Mean serum creatinine and categories of estimated glomerular filtration rate (eGFR) in the general population cohort.

Variables	Mean (95% CI)
<b>Measurements</b>	
Serum creatinine (mg/dl)	0.75 (0.74–0.75)
eGFR (ml/min/1.73m <sup>2</sup> )	
CKD-EPI equation* <sup>1</sup>	109.3 (108.8–109.9)
MDRD equation*	106.2 (105.4–107.1)
	Individuals n(%)
<b>Category of level of eGFR</b>	
Normal eGFR (≥90 ml/min per 1.73 m <sup>2</sup> )	4,792 (80.15)
Low eGFR (60–89 ml/min per 1.73 m <sup>2</sup> )	1,089 (18.21)
Moderately reduced eGFR (30–59 ml/min per 1.73 m <sup>2</sup> )	91 (1.52)
Severely reduced eGFR (15–29 ml/min per 1.73 m <sup>2</sup> )	4 (0.07)
Kidney Failure (eGFR <15 ml/min per 1.73 m <sup>2</sup> )	3 (0.05)

\*The CKD-EPI eGFR calculations were used as the primary outcomes in this study; the MDRD equation was used to contrast the difference between the two equations. <sup>1</sup>The coefficient for black race was omitted while using this equation.

or obese; having hypertension (OR 1.60, 95 % CI 1.22-2.11) and HIV-positive status (OR 1.55, 95% CI 1.13-2.04) were associated with impaired kidney function ([Supplementary Table 3](#)).

Comparison of participants with eGFR <60 ml/min/1.73m<sup>2</sup> to those with eGFR >90 ml/min/1.73m<sup>2</sup> revealed that older age,

hypertension and anaemia were independently associated with impaired renal function ([Supplementary Table 4](#)).

The adjusted population attributable fraction of decreased renal function attributable to hypertension and anaemia was 26.4% and 12.8%, respectively.

**Table 3. Final multivariable model of factors independently associated with estimated glomerular filtration rate <60 ml/min per 1.73m<sup>2</sup>.**

Variable	Adjusted OR (95% CI) <sup>1</sup>
<b>Sex</b>	<b>P=0.56</b>
Male	Reference
Female	1.19 (0.64–2.24)
<b>Age Group</b>	<b>P&lt;0.001</b>
<35	Reference
35–44	0.53 (0.05–5.14)
45–54	3.49 (0.86–14.09)
55–64	5.73 (1.47–22.25)
65–74	12.24 (3.27–45.82)
75 +	29.68 (7.99–110.19)
<b>Blood Pressure*<sup>2</sup></b>	<b>P=0.05</b>
Normal	Reference
Pre-Hypertension	1.92 (0.81–4.57)
Hypertension	2.86 (1.15–7.08)
<b>Anaemia<sup>3</sup></b>	<b>P=0.02</b>
Negative	Reference
Positive	2.14 (1.12–4.09)

\*Variables from a previous round (R22) of the GPC where total number of participants may vary: Blood Pressure (n=3,039).

<sup>1</sup>Multivariable model adjusted for age, sex and all independent predictors of eGFR <60ml/min per 1.73 m<sup>2</sup>. OR, odds ratio; 95% CI, 95% confidence interval. <sup>2</sup>Blood pressure classification derived from the National Institute of Health guidelines: Pre-Hypertension was defined as having a systolic blood pressure greater than 120 mmHg but less than 140 mmHg, and a diastolic blood pressure greater than 80 mmHg but less than 90 mmHg. Hypertension was defined as having a systolic blood pressure (BP) greater than or equal to 90mmHg, diastolic BP greater than or equal to 140mmHg. <sup>3</sup>Anaemia was defined as having haemoglobin levels less than 130 g/l in men, 120 g/L in non-pregnant women, and 110 g/l in pregnant women. Only 2,064 individuals had anaemia results from the R24 of the GPC

## Discussion

We found a prevalence of eGFR <60 mL/min per 1.73 m<sup>2</sup> of 1.64% in this predominantly young rural community of Uganda with more than one-fifth of the study participants having eGFR <90 mL/min per 1.73 m<sup>2</sup>. Impaired renal function was strongly associated with age, high blood pressure and anaemia.

Comparing different prevalence estimates of impaired renal function from studies across sub-Saharan Africa is challenging for many reasons. In a meta-analysis of CKD in sub-Saharan Africa by Stanifer *et al.*<sup>3</sup> the overall prevalence was 13.9% but the majority of the studies were conducted among patients with known risk factors for renal disease such as diabetes mellitus, HIV infection and hypertension. Furthermore, only 2% of the included studies used the CKD-EPI formula for calculation of eGFR although, based on limited data, it has been found to be the best estimate of population CKD prevalence<sup>3,4</sup>. The age structure of population varies widely between countries in sub-Saharan

Africa making standardisation to a reference population crucial for comparisons between regions or countries. In addition, the prevalence of risk factors such as HIV infection vary substantially across and within countries.

We found that older age, hypertension and anaemia were associated with impaired renal function. Age is known to be strongly associated with eGFR<sup>3,23,29</sup>. Hypertension is both a cause and a consequence of kidney disease, and in this cross-sectional survey it was not possible to tell whether the participants had hypertension as a cause or consequence of the kidney disease. However there has been a rise in reported levels of hypertension in Uganda, from 13.7%<sup>31</sup> in 1969 to 26.4% in 2015<sup>20</sup>. Anaemia is also often a consequence of kidney disease, or may be due to shared risk-factors such as other chronic diseases. We found that anaemia was associated with kidney disease, even for patients with eGFR <90 ml/min/1.73m<sup>2</sup>, a level of kidney function at which a direct causal effect would not be anticipated. Factors which have been traditionally associated with kidney disease in high-income countries such as smoking, alcohol intake and obesity were not associated with the presence of eGFR <60 mL/min per 1.73 m<sup>2</sup> in this population. This may be because of the low prevalence of these factors in the community, or may suggest that the risk factors for CKD are different in this region. Indeed, other researchers have found that the majority of kidney disease in SSA is not explained by traditional risk factors<sup>32</sup>.

## Study strengths and limitations

This was a large community-based study conducted within a well-characterized population cohort. We used the CKD-Epi formula to determine eGFR, which is thought to be the best estimate of true GFR in sub-Saharan Africa. We measured a wide range of social and anthropometric factors, chronic diseases and biochemical measurements in a structured and validated manner. In addition, our prevalence estimates have been standardized to the WHO population to enable comparability with other studies across the world.

However, there were limitations, including lack of screening for urine abnormalities (proteinuria and hematuria) which could have led us to underestimate the prevalence of kidney disease. Newer classifications of CKD require measurement of proteinuria to define kidney disease<sup>4</sup>. We only measured creatinine on one occasion while two results of eGFR <60 mL/min per 1.73 m<sup>2</sup> more than 3 months apart are required for the formal definition of CKD. This may have led to an overestimate of the prevalence of impaired renal function. However, most large scale epidemiological surveys have use one measurement of creatinine<sup>33</sup>. In addition, our study was prospectively sampled from well people and are thus likely to be affected by a transient fall in eGFR associated with acute illness. This is in contrast to many studies using routinely collected data to define renal function where misclassification is likely if blood tests are measured during when patients are unwell<sup>34</sup>. Even if we had two measures of creatinine we would not have been able to confidently assert that patients with eGFR <60 mL/min per 1.73 m<sup>2</sup> had 'chronic kidney disease' as the estimating equations are not validated in



sub-Saharan Africa and the long-term outcome implications, on which the CKD categorisation was defined, are not yet understood in this setting.

### Implications of the study

Interventions for end-stage renal disease are currently limited for most countries in sub-Saharan Africa with very poor access to dialysis and kidney transplantation<sup>9,35</sup>. This study has established a significant prevalence of impaired renal function, highlighting the need to focus efforts on preventive strategies to delay onset and slow progression of renal disease. However, marked uncertainty remains about how best to estimate GFR in black Africans. This highlights the importance of our ongoing prospective study to determine the best way to measure renal function in sub-Saharan Africa: <http://blogs.lshtm.ac.uk/ark/>.

### Conclusions

We found that approximately one in five adults in rural Uganda had impaired renal function despite a low prevalence of diabetes and obesity. Impaired renal function was strongly associated with high blood pressure and anaemia. More detailed studies are required to further determine specific risk-factors for impaired renal function and its progression.

### Data availability

Owing to data protection concerns, there are restrictions on access to the underlying data. The GPC database contains

25 years of longitudinal data sets on demographics and disease surveillance. All data (census, survey and laboratory) generated through the cohort are stored and curated at the MRC/UVRI and the LSHTM Research Unit. Data access for specific research purposes is possible and has been granted previously. For any data access inquiries, you may contact the director, MRC/UVRI and the LSHTM Research Unit or by email to [mrc@mrcuganda.org](mailto:mrc@mrcuganda.org) or the corresponding author.

---

### Grant information

RK is funded by a grant from GlaxoSmithKline Africa Non-Communicable Disease Open Lab (Project Number: 8111) as part of a broader multicenter collaborative study between South Africa, Uganda, Malawi and the London School of Hygiene and Tropical Medicine which is collectively identified as the African Research in Kidney Disease (ARK) Network. LAT is funded by a Wellcome Trust intermediate clinical fellowship (101143/Z/13/Z).

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

### Acknowledgements

We would like to thank the General Population Cohort team, which helped in the collection of data and implementation of the study and all the participants.

### Supplementary material

Supplementary Table 1. Factors associated with estimated glomerular filtration rate (eGFR) <60 ml/min per 1.73 m<sup>2</sup> among a general population cohort from rural Uganda.

[Click here to access the data.](#)

Supplementary Table 2. Factors associated with estimated glomerular filtration rate (eGFR) <90 ml/min per 1.73 m<sup>2</sup> among a general population cohort from rural Uganda.

[Click here to access the data.](#)

Supplementary Table 3. Final multivariable model of factors independently associated with estimated glomerular filtration rate (eGFR) <90 ml/min per 1.73 m<sup>2</sup> among a general population cohort from rural Uganda.

[Click here to access the data.](#)

Supplementary Table 4. Final multivariable model of factors independently associated with CKD comparing individuals with estimated glomerular filtration rate (eGFR) ≥90 ml/min per 1.73 m<sup>2</sup> to individuals with eGFR <60 ml/min per 1.73 m<sup>2</sup>.

[Click here to access the data.](#)

Supplementary File 1. GPC questionnaire regarding sexual behaviour and lifestyle factors.

[Click here to access the data.](#)

## References

1. Lozano R, Naghavi M, Foreman K, *et al.*: **Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.** *Lancet.* 2012; **380**(9859): 2095–2128. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Jha V, Garcia-Garcia G, Iseki K, *et al.*: **Chronic kidney disease: global dimension and perspectives.** *Lancet.* 2013; **382**(9888): 260–272. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Stanifer JW, Jing B, Tolan S, *et al.*: **The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis.** *Lancet Glob Health.* 2014; **2**(3): e174–181. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Levey AS, Stevens LA, Schmid CH, *et al.*: **A new equation to estimate glomerular filtration rate.** *Ann Intern Med.* 2009; **150**(9): 604–612. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Lucas GM, Clarke W, Kagaayi J, *et al.*: **Decreased kidney function in a community-based cohort of HIV-infected and HIV-negative individuals in Rakai, Uganda.** *J Acquir Immune Defic Syndr.* 2010; **55**(4): 491–494. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Odongo P, Wanyama R, Obol JH, *et al.*: **Impaired renal function and associated risk factors in newly diagnosed HIV-infected adults in Gulu Hospital, Northern Uganda.** *BMC Nephrol.* 2015; **16**: 43. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Mulenga LB, Kruse G, Lakhi S, *et al.*: **Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia.** *AIDS.* 2008; **22**(14): 1821–1827. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Peck RN, Shedafa R, Kalluvya S, *et al.*: **Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study.** *BMC Med.* 2014; **12**: 125. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Kalyesubula R, Nankabirwa JI, Ssinabulya I, *et al.*: **Kidney disease in Uganda: a community based study.** *BMC Nephrol.* 2017; **18**(1): 116. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Babua C, Kalyesubula R, Okello E, *et al.*: **Pattern and presentation of cardiac diseases among patients with chronic kidney disease attending a national referral hospital in Uganda: a cross sectional study.** *BMC Nephrol.* 2015; **16**: 126. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Stöhr W, Walker AS, Munderi P, *et al.*: **Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and Modification of Diet in Renal Disease formulae.** *Antivir Ther.* 2008; **13**(6): 761–770. [PubMed Abstract](#)
12. Addo J, Smeeth L, Leon DA: **Hypertensive target organ damage in Ghanaian civil servants with hypertension.** *PLoS One.* 2009; **4**(8): e6672. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Fatiu A, Abubakr S, Muzamil H, *et al.*: **Undiagnosed hypertension and proteinuria in a market population in Ile-Ife, Nigeria.** *Arab J Nephrol Transplant.* 2011; **4**(3): 141–146. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Afolabi MO, Abioye-Kuteyi EA, Arogandade FA, *et al.*: **Prevalence of chronic kidney disease in a Nigerian family practice population.** *S Afr Fam Pract.* 2009; **51**(2): 132–137. [Publisher Full Text](#)
15. Abu-Aishaa H, Elhassan A, Khamis A, *et al.*: **Chronic Kidney Disease in Police Forces Households in Khartoum, Sudan: Pilot Report.** *Arab J Nephrol Transplant.* 2009; **2**(2): 21–26. [Publisher Full Text](#)
16. Sumaili EK, Krzesinski JM, Zinga CV, *et al.*: **Prevalence of chronic kidney disease in Kinshasa: results of a pilot study from the Democratic Republic of Congo.** *Nephrol Dial Transplant.* 2009; **24**(1): 117–122. [PubMed Abstract](#) | [Publisher Full Text](#)
17. Okuthe JO, Candy GP, Meyers AM, *et al.*: **Evaluating Kidney Function in Living Donors in South Africa.** *S Afr J Surg.* 2017; **55**(2): 73–74. [PubMed Abstract](#)
18. Glaser N, Phiri S, Bruckner T, *et al.*: **The prevalence of renal impairment in individuals seeking HIV testing in Urban Malawi.** *BMC Nephrol.* 2016; **17**(1): 186. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Deckert A, Neuhann F, Klose C, *et al.*: **Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia.** *PLoS One.* 2017; **12**(9): e0184766. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Guwatudde D, Mutungi G, Wesonga R, *et al.*: **The Epidemiology of Hypertension in Uganda: Findings from the National Non-Communicable Diseases Risk Factor Survey.** *PLoS One.* 2015; **10**(9): e0138991. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Kalyesubula R, Kayongo A, Semitala FC, *et al.*: **Trends and level of control of hypertension among adults attending an ambulatory HIV clinic in Kampala, Uganda: a retrospective study.** *BMJ Glob Health.* 2016; **1**(3): e000055. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Bahendeka S, Wesonga R, Mutungi G, *et al.*: **Prevalence and correlates of diabetes mellitus in Uganda: a population-based national survey.** *Trop Med Int Health.* 2016; **21**(3): 405–416. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Kaze FF, Meto DT, Halle MP, *et al.*: **Prevalence and determinants of chronic kidney disease in rural and urban Cameroonians: a cross-sectional study.** *BMC Nephrol.* 2015; **16**: 117. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Asiki G, Murphy G, Nakiyingi-Miiró J, *et al.*: **The general population cohort in rural south-western Uganda: a platform for communicable and non-communicable disease studies.** *Int J Epidemiol.* 2013; **42**(1): 129–141. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Mugisha JO, Baisley K, Asiki G, *et al.*: **Prevalence, types, risk factors and clinical correlates of anaemia in older people in a rural Ugandan population.** *PLoS One.* 2013; **8**(10): e78394. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Galiwango RM, Musoke R, Lubyayi L, *et al.*: **Evaluation of current rapid HIV test algorithms in Rakai, Uganda.** *J Virol Methods.* 2013; **192**(1–2): 25–27. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Myers GL, Miller WG, Coresh J, *et al.*: **Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program.** *Clin Chem.* 2006; **52**(1): 5–18. [PubMed Abstract](#) | [Publisher Full Text](#)
28. Riha J, Karabarinde A, Ssenyomo G, *et al.*: **Urbanicity and lifestyle risk factors for cardiometabolic diseases in rural Uganda: a cross-sectional study.** *PLoS Med.* 2014; **11**(7): e1001683. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Eastwood JB, Kerry SM, Plange-Rhule J, *et al.*: **Assessment of GFR by four methods in adults in Ashanti, Ghana: the need for an eGFR equation for lean African populations.** *Nephrol Dial Transplant.* 2010; **25**(7): 2178–2187. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
30. National Kidney Foundation: **K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.** *Am J Kidney Dis.* 2002; **39**(2 Suppl 1): S1–266. [PubMed Abstract](#)
31. Shaper AG, Saxton GA: **Blood pressure and body build in a rural community in Uganda.** *East Afr Med J.* 1969; **46**(5): 228–245. [PubMed Abstract](#)
32. Stanifer JW, Maro V, Egger J, *et al.*: **The epidemiology of chronic kidney disease in Northern Tanzania: a population-based survey.** *PLoS One.* 2015; **10**(4): e0124506. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Glasscock RJ, Warnock DG, Delanaye P: **The global burden of chronic kidney disease: estimates, variability and pitfalls.** *Nat Rev Nephrol.* 2017; **13**(2): 104–114. [PubMed Abstract](#) | [Publisher Full Text](#)
34. Stevens PE, O'Donoghue DJ, de Lusignan S, *et al.*: **Chronic kidney disease management in the United Kingdom: NEOERICA project results.** *Kidney Int.* 2007; **72**(1): 92–9. [PubMed Abstract](#) | [Publisher Full Text](#)
35. Bello AK, Levin A, Tonelli M, *et al.*: **Assessment of Global Kidney Health Care Status.** *JAMA.* 2017; **317**(18): 1864–1881. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

# Open Peer Review

Current Referee Status:  

---

## Version 2

Referee Report 17 January 2019

<https://doi.org/10.21956/wellcomeopenres.16352.r34526>



**Kajiru G Kilonzo**

Internal Medicine Department, Kilimanjaro Christian Medical Center, Moshi, Tanzania

Thank you for the opportunity to review this article again.

### **General Comments**

A well written article and very relevant problem being questioned. The use of a General Population Cohort which is well documented is an opportunity to follow them up further. Use of the CKD epi formula is a good addition among published data in Africa. This work could be indexed with some additional work.

I still think the article has important information to share to the scientific community even though the disease has not been defined properly. Efforts to define the link between impaired kidney function and CKD which is the assumed disease could be further made. Why is impaired kidney function a poor man's estimate of chronic kidney disease in a community study? I note that this is somewhat discussed. More is needed to justify using impaired kidney function and CKD interchangeably.

One way of looking at this is from the following argument derived from the authors' data. From the multivariable analysis hypertension and anaemia are likely manifestations of chronic kidney disease, so it is not unreasonable to presume that impaired kidney function is an estimate of CKD.

The study highlights the importance of determining the best way of estimating CKD from the community. This statement could be more emphasized. This could be coming out as the discussion point instead of a study limitation.

### **Abstract**

Very representative of the work. Include a recommendation from your conclusion if possible.

### **Introduction**

This part explains very clearly the importance of CKD, the unavailability of quality data and the variability of impaired renal function.

- Again, in the flow of thoughts, the transition between CKD and impaired renal function has not been linked.

- The last sentence of the second paragraph "Late diagnosis....." appears to be an original idea/conclusion. Rural populations have lower prevalence of CKD. (Stanifer et al., 2015<sup>1</sup>). This could be included in the discussion as well.

Otherwise some justification for doing the study (as stated above) are clear.

### **Methods**

As the last statement of the introduction emphasizes on high quality sampling methods, It could be clearer how the authors sampled 5979 individuals from the 22,000 population. What was the sampling method? The population is within a prospective cohort study. Is it not true that the data collected was cross sectional?

### **Discussion**

The prevalence found of 1.6% is significantly low compared to the global prevalence of CKD. This needs to be discussed in light of the definitions used. Impaired renal function vs CKD. Remember while you hypothesize that the rural population have more CKD, this cohort has very low levels of decreased eGFR. The strength would be in discussing this.

The second paragraph delineates why the results are not comparable, why not use studies which used the same measure of impaired renal function? Furthermore, the use of MDRD to estimate the eGFR can not explain such a huge difference in prevalence. Again, this needs to come out.

In the risk factor paragraph, the authors mention that the traditional risks are not seen. Is there CKDu?

### **Conclusions**

It was not clear from the study why more data on risk factors is needed.

### **References**

1. Stanifer JW, Jing B, Tolan S, Helmke N, Mukerjee R, Naicker S, Patel U: The epidemiology of chronic kidney disease in sub-Saharan Africa: a systematic review and meta-analysis. *Lancet Glob Health*. 2014; **2** (3): e174-81 [PubMed Abstract](#) | [Publisher Full Text](#)

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** Peritoneal dialysis, Acute Kidney disease, CKD

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Referee Report 04 January 2019

<https://doi.org/10.21956/wellcomeopenres.16352.r34525>



### **John Feehally**

University of Leicester, Leicester, UK

The authors have responded very satisfactorily to the reservations I expressed. The term 'impaired renal function' is now used rather than CKD since their methodology does not allow formal identification of CKD. The discussion is significantly improved in reviewing the limitations as well as strengths of the study.

Two typos should be corrected:

Discussion: Study Strengths & Limitations, para 2, line 6. The sentence should read: "*In addition our study*

was prospectively sampled from well people and is this **unlikely** to be affected by any transient falls in eGFR associated with acute illness”

Discussion: Study Strengths & Limitations, para 2, line 8. The word ‘during’ should be deleted. The sentence should read: “..... if blood tests are measured when people are unwell.”

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** I am a recently retired UK academic nephrologist with a 15 year experience in leadership of the International Society of Nephrology which has a primary focus on improving kidney care in low and middle income countries. I lead capacity building programs for that society, including education and research training, and have a major focus on the challenges this represents in sub-Saharan Africa.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

---

## Version 1

Referee Report 17 December 2018

<https://doi.org/10.21956/wellcomeopenres.16198.r34316>



### Kajiru G Kilonzo

Internal Medicine Department, Kilimanjaro Christian Medical Center, Moshi, Tanzania

This well written work has the aim to alert us of the presence of kidney diseases in a rural cohort. Even though the introduction could be built towards the question of the risk factors in view of CKD unknown, the idea is to provide us with a starting point for epidemiological discussion in rural Africa.

The methodology has the strength of measuring serum creatinine using a standardized assay. And CKD Epi formula is an advantage. The main weakness is the use of one serum creatinine which actually brings up an ethical question in this General Population Cohort (1989, UK funded) especially for those found to have CKD. A report on what happened to them would be helpful. And hence the use of impaired renal function would fit more appropriately instead of CKD.

**Is the work clearly and accurately presented and does it cite the current literature?**

Partly

**Is the study design appropriate and is the work technically sound?**

Partly

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

No

**Are the conclusions drawn adequately supported by the results?**

Partly

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** Peritoneal dialysis, Acute Kidney disease, CKD

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 18 Dec 2018

**Laurie Tomlinson, LSHTM, UK**

Dear Professor Kilonzo,

Many thanks for your review of our paper. You raise very similar concerns to Professor Feehally and we agree with the issues you have raised. We hope that our new draft of the paper fully addresses these concerns.

We very much agree about the importance of understanding renal and other outcomes among the cohort we have examined here. This work is underway as part of the ARK study (<http://blogs.lshtm.ac.uk/ark/>) and we will be able to report on changes in renal function and mortality rates at different levels of renal function when this work is complete.

**Competing Interests:** None

Referee Report 03 December 2018

<https://doi.org/10.21956/wellcomeopenres.16198.r34314>



**John Feehally**

University of Leicester, Leicester, UK

This is in many ways a very well-executed population cohort study of adults in rural Uganda, with the aim of identifying chronic kidney disease (CKD) and associated risk factors. The organisational and logistic challenges of such a cohort study in rural sub-Saharan Africa are well understood, and the authors are to be congratulated for their achievement. The methods, result and discussion are all very clearly written.

However the study has one fundamental design flaw. CKD is a chronic condition, and by definition can only be confirmed when serum creatinine is measured, and from that GFR is estimated, on two separate occasions. Prevalence can be misleading when a single measurement is used.

The authors themselves recognise this in the final sentence of 'Study Strengths & Limitations': "We only measured creatinine on one occasion; two screenings are required for the formal definition of CKD."

Regrettably a substantial proportion of the CKD epidemiology literature is flawed by reliance on a single

measurement of kidney function, and claiming to identify CKD. This is particularly so in studies from low and middle income countries.

The challenge of recalling a study cohort for second sampling is recognised and understood, especially in a low resource setting, such as Uganda. But in the opinion of this reviewer does not justify the report here submitted. While the majority of those identified in this study are likely to have CKD, it is not sound to report these data as showing the prevalence of CKD, when a fundamental aspect of the epidemiological definition of CKD has not been accounted for.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

No

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

No

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** I am a recently retired UK academic nephrologist with a 15 year experience in leadership of the International Society of Nephrology which has a primary focus on improving kidney care in low and middle income countries. I lead capacity building programs for that society, including education and research training, and have a major focus on the challenges this represents in sub-Saharan Africa.

**I have read this submission. I believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.**

Author Response 14 Dec 2018

**Laurie Tomlinson, LSHTM, UK**

Dear Professor Feehally,

Many thanks for your helpful comments on the first draft of this paper. While the vast majority of epidemiological surveys are based on one measure of creatinine, we fully agree that this is limited and indeed had tried to make this point. We have now fully revised the paper in line with your suggestions to make our approach and the limitations clear. We have also discussed in more depth the need for better quality research into the prevalence of kidney disease in sub-Saharan

Africa in terms of population sampling, creatinine measurement and understanding how best to estimate GFR from creatinine levels in this population. This paper provides the first stage of a large ongoing study to do exactly this: <http://blogs.lshtm.ac.uk/ark/> .We hope that this draft will now meet your approval.

**Competing Interests:** No competing interests were disclosed.